Literature DB >> 22537397

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

Angela Dispenzieri1, Morie A Gertz, Francis Buadi.   

Abstract

Immunoglobulin light chain (AL) amyloidosis is the most common acquired systemic amyloidoses. Its presentation is often insidious and progressive, which may delay diagnosis. The interval between first symptoms and actual diagnosis along the intrinsic heterogeneity of tissue tropism create a wide spectrum of presentations, both in terms of scope and depth of symptoms and signs and functional status of patients. In this review, the authors review the pathogenesis, diagnosis and differential diagnosis of AL amyloidosis along with the prognosis and state-of-the-art management for patients with this affliction.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537397     DOI: 10.1016/j.blre.2012.03.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  36 in total

Review 1.  New insights and modern treatment of AL amyloidosis.

Authors:  Chakra P Chaulagain; Raymond L Comenzo
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

3.  A residue-specific shift in stability and amyloidogenicity of antibody variable domains.

Authors:  Cardine N Nokwe; Martin Zacharias; Hisashi Yagi; Manuel Hora; Bernd Reif; Yuji Goto; Johannes Buchner
Journal:  J Biol Chem       Date:  2014-08-05       Impact factor: 5.157

4.  Macrophage-Mediated Phagocytosis and Dissolution of Amyloid-Like Fibrils in Mice, Monitored by Optical Imaging.

Authors:  Tina Richey; James S Foster; Angela D Williams; Anna B Williams; Alexa Stroh; Sallie Macy; Craig Wooliver; R Eric Heidel; Siva K Varanasi; Elizabeth N Ergen; Dianne J Trent; Stephen A Kania; Stephen J Kennel; Emily B Martin; Jonathan S Wall
Journal:  Am J Pathol       Date:  2019-02-06       Impact factor: 4.307

Review 5.  Disease-modifying therapy for proteinopathies: Can the exception become the rule?

Authors:  Gal Bitan
Journal:  Prog Mol Biol Transl Sci       Date:  2019-08-07       Impact factor: 3.622

6.  Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.

Authors:  Jonathan S Wall; James S Foster; Emily B Martin; Stephen J Kennel
Journal:  Pharm Pat Anal       Date:  2017-08-21

7.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Anita D'Souza; Angela Dispenzieri; Baldeep Wirk; Mei-Jie Zhang; Jiaxing Huang; Morie A Gertz; Robert A Kyle; Shaji Kumar; Raymond L Comenzo; Robert Peter Gale; Hillard M Lazarus; Bipin N Savani; Robert F Cornell; Brendan M Weiss; Dan T Vogl; César O Freytes; Emma C Scott; Heather J Landau; Jan S Moreb; Luciano J Costa; Muthalagu Ramanathan; Natalie S Callander; Rammurti T Kamble; Richard F Olsson; Siddhartha Ganguly; Taiga Nishihori; Tamila L Kindwall-Keller; William A Wood; Tomer M Mark; Parameswaran Hari
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

8.  Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

Authors:  Luis M Blancas-Mejía; Jared Hammernik; Marta Marin-Argany; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 9.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

10.  Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.

Authors:  Taxiarchis V Kourelis; Shaji K Kumar; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Steven Zeldenrust; Nelson Leung; Robert A Kyle; Stephen Russell; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; S Vincent Rajkumar; Arleigh McCurdy; Angela Dispenzieri
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.